CAI
Clinical Asset Index
by VOS Supply Group
Drugs · acquisition-cost intelligence

LOREEV XR

lorazepam· ingredient lorazepam· LORAZEPAM 1.5 mg/1; LORAZEPAM 1 mg/1; LORAZEPAM 2 mg/1; LORAZEPAM 3 mg/1
What this is. Acquisition-cost intelligence for pharmacy & clinic buyers — the historical trend, generic-equivalent costs, and Part D posture. NADAC is a pharmacy acquisition cost (the national average pharmacies pay), not a retail or cash price — for consumer cash prices use GoodRx/your plan.
Acquisition benchmark · NADAC per EA
$14.24
NADAC — pharmacy acquisition cost, not a retail/cash price

Acquisition-cost history

Weekly NADAC per EA — the trend nobody else shows. 6 weeks.

2025-12-172026-05-20

Same-ingredient options by acquisition cost

Other lorazepam products, cheapest acquisition cost first. Per EA — confirm strength/form equivalence before switching.

ProductNADAC / EAvs this
Lorazepam$0.03293−$14.21
Lorazepam$0.63219−$13.61
Lorazepam$1.82−$12.42
Lorazepam$1.82−$12.42

Sources: CMS NADAC (pharmacy acquisition cost), FDA NDC + RxNorm (identity), RxClass (therapeutic class), CMS Medicare Part D formulary (coverage). Observed reference data for professional buyers — not a retail/cash price, not pricing or medical advice. Verify before purchasing or substituting.